JOURNAL ARTICLE

New radioactive isotope therapies promise more targeted attacks on cancer.

  • Published In: Sciencemag.org, 2025. P. N.PAG 1 of 3

  • Database: Applied Science & Technology Source Ultimate 2 of 3

  • Authored By: Service, Robert F. 3 of 3

Abstract

The article focuses on the advancements in radiopharmaceuticals, particularly the development of new cancer therapies that utilize radioactive isotopes to target cancer cells more precisely. It highlights the increasing demand for actinium-225 (Ac-225), a key isotope in these therapies, and the challenges associated with its production, which is currently limited to facilities like Oak Ridge National Laboratory. The article discusses the evolution of radiopharmaceuticals, including the shift towards alpha emitters, which may offer more effective cancer treatment with fewer side effects compared to traditional chemotherapy. Additionally, it notes the significant investment and interest from pharmaceutical companies in this burgeoning field, driven by recent clinical successes of targeted therapies. [Extracted from the article]

Additional Information

  • Source:Sciencemag.org. 2025/10, pN.PAG
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2025
  • Accession Number:188431570
  • Copyright Statement:Copyright of Sciencemag.org is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.